News & Views
Research Focused on CNS Disease
Jan 08 2019
Domain Therapeutics (Strasbourg) and Boehringer Ingelheim are collaborating in a multi-target drug discovery and licensing agreement on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area.
Domain Therapeutics will use its proprietary platforms, DTect-All™ and bioSens-All™, which enable characterisation of small molecule GPCR binders for the screening of potential lead compounds. Domain will be eligible for an upfront payment, discovery, development and commercial milestone payments as well as royalties on sales. Financial details were not disclosed.
“We are excited to initiate the collaboration with Domain Therapeutics, a leading player in the GPCR space. This collaboration helps us to bolster our CNS research efforts,” said Dr Bernd Sommer, Global Head, CNS Diseases Research at Boehringer Ingelheim. “We have a valuable partner with complementary expertise and key technologies that allow us to accelerate research and development in this area of great unmet medical need.”
“With its focus on emerging science and breakthrough medicines, we are enthusiastic to be working with Boehringer Ingelheim,” said Pascal Neuville, CEO of Domain Therapeutics. “We believe that our approach and technologies will allow for the identification of new drug candidates against these challenging targets and coupled with Boehringer Ingelheim’s strength and expertise, their rapid advancement into the clinic.”
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 11 2024 Dusseldorf, Germany
Nov 12 2024 Cologne, Germany
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan